Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-04-13Clinical Trial Update: Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension [NA]
Clinical trial evaluating right ventricular substrate metabolism as a predictor of right heart failure in patients with pulmonary arterial h…
-
CLINICAL_TRIALS trial_result · 2018-04-09Clinical Trial Update: Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
A completed non-interventional, multi-center study evaluated routine inhaled iloprost therapy for pulmonary arterial hypertension delivered …
-
CLINICAL_TRIALS trial_result · 2018-03-27Clinical Trial Update: BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension [NA]
The BEET PAH trial assessing the effects of beetroot juice in patients with pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2018-03-23Clinical Trial Update: Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging [NA]
A Massachusetts General Hospital clinical trial evaluating pulmonary perfusion heterogeneity and lung compliance in patients with pulmonary …
-
CLINICAL_TRIALS trial_result · 2018-03-07Clinical Trial Update: Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension [NA]
A completed clinical trial examines peripheral muscle microcirculation and exercise-induced blood flow distribution in pulmonary arterial hy…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2018-03-07Clinical Trial Update: Pulmonary Arterial Hypertension in Systemic Sclerosis
Update on a clinical trial examining pulmonary arterial hypertension in patients with systemic sclerosis (NCT00617487); current status is no…
-
CLINICAL_TRIALS withdrawal · 2018-03-06Clinical Trial Update: Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan [Phase 4]
A Phase 4 study investigating bosentan for pulmonary arterial hypertension secondary to idiopathic pulmonary fibrosis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-02-05Clinical Trial Update: A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain [Phase 3]
Phase 3 study of macitentan to validate PAH-SYMPACT in France, Italy and Spain was terminated with results posted in 2018.
-
FDA approval · 2018-02-01FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
The FDA approved Pfizer's supplemental application for Revatio (sildenafil citrate), indicating FDA approval of the requested changes to the…
-
CLINICAL_TRIALS trial_result · 2018-01-30Clinical Trial Update: Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome [Phase 3]
Phase 3 trial evaluating the effects of macitentan on exercise capacity in Eisenmenger syndrome completed with posted results in 2018.
-
CLINICAL_TRIALS trial_result · 2018-01-18Clinical Trial Update: Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 clinical trial evaluating the effect of morphine on dyspnea and 6-minute walk distance in patients with pulmonary arterial hypertens…
-
FDA approval · 2018-01-11FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approves a supplemental application for ADEMPAS (riociguat) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2017-12-28Clinical Trial Update: Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension [Phase 3]
Phase 3 trial evaluating tolerability and safety of transitioning from inhaled treprostinil to oral selexipag in patients with pulmonary art…
-
FDA label_change · 2017-12-20FDA Approved: UPTRAVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA lists a supplemental application for UPTRAVI (selexipag) filed by Actelion Pharmaceuticals US, Inc.
-
FDA approval · 2017-12-14FDA Approved: SILDENAFIL CITRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for sildenafil citrate submitted by Mylan Pharmaceuticals Inc., resulting in an approved modific…
-
CLINICAL_TRIALS trial_result · 2017-12-11Clinical Trial Update: FUTURE 3 Study Extension [Phase 3]
Actelion reported the FUTURE 3 study extension for pulmonary arterial hypertension has completed and results were posted in 2017.
-
CLINICAL_TRIALS research · 2017-12-04Clinical Trial Update: Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
Observational update describing adherence to daily Ventavis (iloprost) use via the Insight program in Class III pulmonary arterial hypertens…
-
FDA approval · 2017-11-30FDA Approved: TREPROSTINIL — Original Application (Sandoz Inc)
FDA approved an original-application generic Treprostinil water solution from Sandoz Inc for the treatment of pulmonary arterial hypertensio…
-
CLINICAL_TRIALS withdrawal · 2017-11-01Clinical Trial Update: Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension [Phase 3]
A Phase 3 study comparing triple therapy (oral treprostinil, ambrisentan, and tadalafil) with dual therapy (ambrisentan, tadalafil, and plac…
-
CLINICAL_TRIALS trial_result · 2017-10-24Clinical Trial Update: A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 trial evaluating different oral doses of PF-00489791 for adults with pulmonary arterial hypertension was terminated, with results …
-
FDA approval · 2017-10-20FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for Tracleer (bosentan) from Actelion Pharmaceuticals US, expanding its regulatory approval. The act…
-
FDA approval · 2017-10-20FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA notes Actelion's supplemental NDA for Tracleer (bosentan) and the agency's approval of the supplemental application.
-
FDA approval · 2017-10-19FDA Approved: TYVASO — Supplemental Application (United Therapeutics Corporation)
FDA approved a supplemental application for TYVASO (treprostinil) filed by United Therapeutics Corporation.
-
CLINICAL_TRIALS trial_result · 2017-10-17Clinical Trial Update: Efficacy of Ventavis Used in Real-life Setting.
This clinical trial update reports on the real-world efficacy of Ventavis (iloprost) for pulmonary arterial hypertension.
-
CLINICAL_TRIALS trial_result · 2017-10-16Clinical Trial Update: Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) [Phase 4]
A Phase 4 clinical trial update reports results for a thermostable epoprostenol sodium formulation intended to treat pulmonary arterial hype…